Literature DB >> 20128022

Hepatitis D: Scenario in the Asia-Pacific region.

Zaigham Abbas1, Wasim Jafri, Sajjad Raza.   

Abstract

Hepatitis D virus (HDV) infection is present worldwide and affects all age groups. Around 18 million people are estimated to be infected with HDV. An important trend in HDV infection is global decline. HDV prevalence has decreased significantly in Europe since the 1970s and 1980s when it was first reported. The Asia-Pacific region now seems to be where HDV is a major health concern. There is a lack of available data from most of the countries from this region; hence, the true status of HDV cannot be determined. In South Asia, most of the countries have conditions that are favorable for the spread of hepatitis B and other related infections. Countries like Pakistan and Iran have shown an increase in HDV prevalence over a period of time. Other countries and region like China, Turkey, Australia, Japan, India and Taiwan, some of which had very high HDV prevalence in the past, have shown a decline in the incidence, but high prevalence persists in some. Intravenous drug abusers, homosexual men and women, prostitutes, and people on hemodialysis are the groups with very high HDV prevalence.

Entities:  

Mesh:

Year:  2010        PMID: 20128022      PMCID: PMC2816266          DOI: 10.3748/wjg.v16.i5.554

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  92 in total

1.  Delta hepatitis in Turkey: decreasing but not vanishing and still of concern.

Authors:  Cihan Yurdaydin
Journal:  Turk J Gastroenterol       Date:  2006-03       Impact factor: 1.852

2.  Delta hepatitis virus infection in China.

Authors:  D Q Wang; H H Cheng; G Y Minuk; L H Liu; C M Anand; T C Stowe; H X Wang; D C Ying; Y R Tu; K A Buchan
Journal:  Int J Epidemiol       Date:  1987-03       Impact factor: 7.196

3.  Hepatitis D virus infection among intravenous drug abusers in Taiwan: analysis of risk factors and liver function tests.

Authors:  H M Hsu; Y F Wang; S H Lo; H C Sun; K K Yip; J S Chen; C H Chuang; D S Chen
Journal:  J Med Virol       Date:  1990-06       Impact factor: 2.327

4.  Prevalence of anti-delta antibodies in central India.

Authors:  S P Jaiswal; D S Chitnis; K K Artwani; G Naik; A K Jain
Journal:  Trop Gastroenterol       Date:  1999 Jan-Mar

5.  Hepatitis delta virus infection among the tribes of the Andaman and Nicobar Islands, India.

Authors:  M V Murhekar; K M Murhekar; V A Arankalle; S C Sehgal
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-07       Impact factor: 2.184

6.  Hepatitis D virus infection in Thailand: HDV genotyping by RT-PCR, RFLP and direct sequencing.

Authors:  A Theamboonlers; T Hansurabhanon; V Verachai; V Chongsrisawat; Y Poovorawan
Journal:  Infection       Date:  2002-06       Impact factor: 3.553

7.  Epidemiology of hepatitis D virus (delta) infection in Melbourne over a 15-year period.

Authors:  M Dimitrakakis; M J Waters; A L Wootton; I D Gust
Journal:  Med J Aust       Date:  1986 Aug 4-18       Impact factor: 7.738

8.  Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis.

Authors:  Halil Değertekin; Kendal Yalçin; Mustafa Yakut; Cihan Yurdaydin
Journal:  Liver Int       Date:  2008-04       Impact factor: 5.828

9.  Hepatitis D anti-bodies in some HBs Ag positive in Saudis at Riyadh.

Authors:  M Massoud; O Helmy; W A Saleh
Journal:  J Egypt Soc Parasitol       Date:  1991-08

10.  Seroprevalence of hepatitis B virus and its co-infection with hepatitis D virus and hepatitis C virus in Iranian adult population.

Authors:  Roshandel Gholamreza; Semnani Shahryar; Keshtkar Abbasali; Joshaghani Hamidreza; Moradi Abdolvahab; Kalavi Khodaberdi; Roshandel Danyal; Abdolahi Nafiseh
Journal:  Indian J Med Sci       Date:  2007-05
View more
  34 in total

Review 1.  The management of chronic hepatitis B in Asian Americans.

Authors:  Myron J Tong; Calvin Q Pan; Hie-Won Hann; Kris V Kowdley; Steven-Huy B Han; Albert D Min; Truong-Sinh Leduc
Journal:  Dig Dis Sci       Date:  2011-09-21       Impact factor: 3.199

2.  Prevalence of hepatitis D virus infection among hepatitis B virus-infected individuals in India.

Authors:  Shankar Lal Jat; Neha Gupta; Tarun Kumar; Swapnil Mishra; Avani S; Vishwajeet Yadav; Amit Goel; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2015-04-24

3.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

4.  Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.

Authors:  Ashish Goyal; John M Murray
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

Review 5.  Life cycle and pathogenesis of hepatitis D virus: A review.

Authors:  Zaigham Abbas; Rafia Afzal
Journal:  World J Hepatol       Date:  2013-12-27

Review 6.  Hepatitis delta virus: Making the point from virus isolation up to 2014.

Authors:  Raffaella Romeo; Riccardo Perbellini
Journal:  World J Hepatol       Date:  2015-10-08

Review 7.  Hepatitis D Virus: Introduction and Epidemiology.

Authors:  Mario Rizzetto
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

Review 8.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

9.  Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.

Authors:  Shaikh Samiullah; Devrajani Bikharam
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

Review 10.  Management of hepatitis delta: Need for novel therapeutic options.

Authors:  Zaigham Abbas; Minaam Abbas
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.